Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency?

Blood

Volumn 116, Issue 8, 2010, Pages 1228-1234

  Vajdic, Claire M ^a   Mao, Limin ^a   Van Leeuwen, Marina T ^a,b   Kirkpatrick, Philippa ^c   Grulich, Andrew E ^b   Riminton, Sean ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; AGED; ARTICLE; ATAXIA TELANGIECTASIA; AUSTRALIA; B LYMPHOCYTE; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CHILD; COMMON VARIABLE IMMUNODEFICIENCY; COMPLEMENT DEFICIENCY; CONFIDENCE INTERVAL; FEMALE; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN A DEFICIENCY; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PHAGOCYTE DYSFUNCTION; PRIMARY IMMUNE DEFICIENCY; PRIORITY JOURNAL; RISK ASSESSMENT; SOLID TUMOR; STOMACH CANCER; T LYMPHOCYTE; X LINKED AGAMMAGLOBULINEMIA;

EID: 77956536491     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-03-272351     Document Type: Article

References (47)

1. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59-67.
2. van Leeuwen MT, Grulich AE, Webster AC, et al. Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood. 2009;114(3):630-637.
3. Clifford GM, Rickenbach M, Lise M, et al. Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood. 2009;113(23):5737-5742.
4. Vajdic CM, van Leeuwen MT, Webster AC, et al. Cutaneous melanoma is related to immune suppression in kidney transplant recipients. Cancer Epidemiol Biomarkers Prev. 2009;18(8):2297-2303.
5. Engels EA, Pfeiffer RM, Landgren O, Moore RD. Immunologic and virologic predictors of AIDS-related non-Hodgkin lymphoma in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr. 2010;54(1):78-84.
6. Landgren O, Goedert JJ, Rabkin CS, et al. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol. 2010;28(5):773-779.
7. Notarangelo LD, Fischer A, Geha RS, et al. Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol. 2009;124(6):1161-1178.
8. Kinlen LJ, Webster AD, Bird AG, et al. Prospective study of cancer in patients with hypogammaglobulinaemia. Lancet. 1985;1(8423):263-266. (Pubitemid 15130644)
9. Cunningham-Rundles C, Siegal FP, Cunningham-Rundles S, Lieberman P. Incidence of cancer in 98 patients with common varied immunodeficiency. J Clin Immunol. 1987;7(4):294-299. (Pubitemid 17146797)
10. Olsen JH, Hahnemann JM, Borresen-Dale AL, et al. Cancer in patients with ataxia-telangiectasia and in their relatives in the Nordic countries. J Natl Cancer Inst. 2001;93(2):121-127. (Pubitemid 32111989)
11. Mellemkjaer L, Hammarstrom L, Andersen V, et al. Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study. Clin Exp Immunol. 2002;130(3):495-500. (Pubitemid 35418334)
12. Taskinen M, Ranki A, Pukkala E, Jeskanen L, Kaitila I, Makitie O. Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma. Am J Med Genet A. 2008;146A(18):2370-2375.
13. Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 263 patients with ataxiatelangiectasia. J Natl Cancer Inst. 1986;77(1):89-92. (Pubitemid 16077187)
14. Baumgart KW, Britton WJ, Kemp A, French M, Roberton D. The spectrum of primary immunodeficiency disorders in Australia. J Allergy Clin Immunol. 1997;100(3):415-423. (Pubitemid 27402786)
15. Kirkpatrick P, Riminton S. Primary immunodeficiency diseases in Australia and New Zealand. J Clin Immunol. 2007;27(5):517-524. (Pubitemid 47319258)
16. Grulich AE, Wan X, Law MG, Coates M, Kaldor JM. Risk of cancer in people with AIDS. AIDS. 1999;13(7):839-843.
17. van Leeuwen MT, Vajdic CM, Middleton MG, et al. Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy. AIDS. 2009;23(16):2183-2190.
18. Australian Institute of Health and Welfare, Australasian Association of Cancer Registries. Cancer Survival in Australia, 2001. AIHW Cancer Series No. 19. Canberra, Australian Capital Territory: Australian Institute of Health and Welfare; 2001.
19. South Australian Cancer Registry. Epidemiology of Cancer in South Australia. Adelaide, South Australia: South Australian Cancer Registry; 2000.
20. Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296(23):2823-2831.
21. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92(18):1500-1510.
22. Li Y, Law M, McDonald A, Correll P, Kaldor JM, Grulich AE. Estimation of risk of cancers before occurrence of acquired immunodeficiency syndrome in persons infected with human immunodeficiency virus. Am J Epidemiol. 2002;155(2):153-158. (Pubitemid 34072738)
23. Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110(2):695-708.
24. Breslow NE, Day NE. Statistical Methods in Cancer Research. Volume II: The Design and Analysis of Cohort Studies. IARC Scientific Publications No. 82. Lyon, France: Oxford University Press; 1987.
25. Filipovich AH, Mathur A, Kamat D, Kersey JH, Shapiro RS. Lymphoproliferative disorders and other tumors complicating immunodeficiencies. Immunodeficiency. 1994;5(2):91-112. (Pubitemid 24122263)
26. Cunningham-Rundles C, Cooper DL, Duffy TP, Strauchen J. Lymphomas of mucosal-associated lymphoid tissue in common variable immunodeficiency. Am J Hematol. 2002;69(3):171-178. (Pubitemid 34177470)
27. International Agency for Research on Cancer (IARC). IARC Monographs on the evaluation of carcinogenic risks to humans: Epstein-Barr virus and Kaposi's sarcoma herpesvirus/human herpesvirus 8, Volume 70. Lyon, France: IARC Press; 1997.
28. Dolcetti R. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders. Autoimmun Rev. 2007;7(2):96-101. (Pubitemid 350116719)
29. Pietersma F, Piriou E, van Baarle D. Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients. Leuk Lymphoma. 2008;49(6):1028-1041. (Pubitemid 351943248)
30. Eyfjord JE, Bodvarsdottir SK. Genomic instability and cancer: networks involved in response to DNA damage. Mutat Res. 2005;592(1-2):18-28. (Pubitemid 41714040)
31. Parolini S, Bottino C, Falco M, et al. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J Exp Med. 2000;192(3):337-346. (Pubitemid 30629159)
32. Bogstedt AK, Nava S,Wadstrom T, Hammarstrom L. Helicobacter pylori infections in IgA deficiency: lack of role for the secretory immune system. Clin Exp Immunol. 1996;105(2):202-204. (Pubitemid 26246934)
33. Akhiani AA. The role of type-specific antibodies in colonization and infection by Helicobacter pylori. Curr Opin Infect Dis. 2005;18(3):223-227. (Pubitemid 40769179)
34. Knekt P, Teppo L, Aromaa A, Rissanen H, Kosunen TU. Helicobacter pylori IgA and IgG antibodies, serum pepsinogen I and the risk of gastric cancer: changes in the risk with extended follow-up period. Int J Cancer. 2006;119(3):702-705. (Pubitemid 43955726)
35. Quiding-Järbrink M, Sundstrom P, Lundgren A, et al. Decreased IgA antibody production in the stomach of gastric adenocarcinoma patients. Clin Immunol. 2009;131(3):463-471.
36. Zullo A, Romiti A, Rinaldi V, et al. Gastric pathology in patients with common variable immunodeficiency. Gut. 1999;45(1):77-81. (Pubitemid 29301849)
37. Deane S, Selmi C, Naguwa SM, Teuber SS, Gershwin ME. Common variable immunodeficiency: etiological and treatment issues. Int Arch Allergy Immunol. 2009;150(4):311-324.
38. Tarr PE, Sneller MC, Mechanic LJ, et al. Infections in patients with immunodeficiency with thymoma (Good syndrome). Report of 5 cases and review of the literature. Medicine (Baltimore). 2001;80(2):123-133. (Pubitemid 32285209)
39. Mehta AC, Faber-Langendoen K, Duggan DB. Common variable immunodeficiency and breast cancer. Cancer Invest. 2004;22(1):93-96. (Pubitemid 38523962)
40. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens - Part B: biological agents. Lancet Oncol. 2009;10(4):321-322.
41. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97(6):425-432. (Pubitemid 40528605)
42. Franceschi S, Maso LD, Rickenbach M, et al. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer. 2008;99(5):800-804.
43. Malphettes M, Gerard L, Carmagnat M, et al. Late-onset combined immune deficiency: a subset of common variable immunodeficiency with severe T cell defect. Clin Infect Dis. 2009;49(9):1329-1338.
44. van Leeuwen MT, Webster AC, McCredie MR, et al. Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ. 2010;340:c570.
45. Carmeli Y, Mevorach D, Kaminski N, Raz E. Regression of Kaposi's sarcoma after intravenous immunoglobulin treatment for polymyositis. Cancer. 1994;73(11):2859-2861. (Pubitemid 24166277)
46. Erdos M, Garami M, Rakoczi E, et al. Neuroendocrine carcinoma associated with X-linked hyperimmunoglobulin M syndrome: report of four cases and review of the literature. Clin Immunol. 2008;129(3):455-461.
47. Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008;112(2):277-286.